Edgewise Therapeutics Appoints John Moore as General Counsel
“Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of John Moore to the newly created position of General Counsel. Mr. Moore has many years of experience as General Counsel for small molecule biopharmaceutical companies working in a range of therapeutic areas. This comes at an important time as Edgewise advances EDG-5506, the company’s lead product candidate, in clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD),” posts Edgewise Therapeutics in News.
“Prior to joining Edgewise, Mr. Moore was General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s initial public offering (IPO) efforts and was a key advisor on its acquisition by Merck on the eve of its planned IPO. Previously, Mr. Moore served for 15 years as General Counsel and Secretary at Array BioPharma Inc., and for 5 years on the board of directors of Nivalis Therapeutics. Mr. Moore began his legal career as an attorney in private practice. Mr. Moore holds a B.S. in chemistry from the University of North Carolina, an M.S. in biochemistry from the University of Illinois and a J.D. from the University of North Carolina.”
